News and Insights from Our Multidisciplinary Team of Experts
OverviewDuring a recent panel discussion, members of the Flagship Biosciences team and representatives from The Johns Hopkins University, Leap Therapeutics, and Corritori Consulting shared their thoughts on companion diagnostics development, with an emphasis on...
Introduction and BackgroundDr. Roberto Gianani, Chief Medical Officer at Flagship Biosciences, Inc., is a practicing pathologist who is board certified in anatomic pathology, clinical pathology, and pediatric pathology. He is fellowship-trained in surgical pathology...
Introduction and BackgroundAdam Beharry, PhD, is a Flagship scientist who describes his work as applying advanced technical knowledge and critical thinking to expand Flagship’s tissue image analysis in neuromuscular and rare diseases. Adam’s degrees include: BS –...
IntroductionThe success of clinical trials is highly dependent on the intricacies of patient recruitment. Other challenges, from the costs of clinical supplies to the specific procedural requirements that can extend physicians’ time, can increase costs. There are also...
Broomfield, CO – June 1, 2021 – Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced that the company has moved its headquarters to a new location in Broomfield, Colorado, just north of Denver. The office, at 11800 Ridge...
Cambridge, MA and Westminster, CO — May 12, 2021 — Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
PUBLICATIONS/POSTERS
Background Dickkopf-1 (DKK1) is a secreted modulator of Wnt signaling that is frequently overexpressed in tumors and associated with a poor prognosis. In this study, we demonstrate an approach for clinically validating a RNAscope chromogenic in-situ hybridization...
Background The Dako PD-L1 (22C3) antibody is used to measure tumor PD-L1 levels in non-small cell lung cancer (NSCLC), serving as a companion diagnostic to the check point inhibitor drug pembrolizumab. However, interpretation of the PD-L1 (22C3) immunohistochemistry...
Key takeaways An image analysis-based algorithm was used to assess CD8 expression in numerous tumor nests in non-small cell lung cancer, bladder, and melanoma tumor samples Measuring CD8 expression within tumor nests rather than averaging across a whole tissue section...
EVENTS
Meet with us at the Spatial Biology for Immuno-Oncology Summit.The Spatial Biology for Immuno-Oncology Summit is back for its second year, and Flagship Biosciences is a Program Partner for the event. Join us January 23-25 in San Diego where key industry leaders will...
Meet with us at the American Society of Hematology annual meeting in December. Whether you’re engaged in basic research or drug development, our genomics solutions offer valuable insights to help you achieve your goals. We offer the highest quality results and support...
Visit Flagship at SITC 2023 Booth #716. November 3-5, 2023. We offer a comprehensive set of discovery, translational and clinical testing, and assay development services to support your clinical studies in immune-oncology and immunotherapy. From the selection of...